Stock Comparison
IFRX vs UNH
InflaRx NV vs UnitedHealth Group Inc
Who's the better investment? Let's break it down.
The Verdict
IFRX takes this one.
It's not even close. IFRX outscores UNH by 3.7 points. That's a significant gap in our deep value framework.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
IFRX
Metric
UNH
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
EV/EBITDA
Profitability & Growth
IFRX
Metric
UNH
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
IFRX
Metric
UNH
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
IFRX
UNH
What Could Go Wrong
The ongoing DOJ criminal and civil investigation, if it leads to significant penalties, forced divestitures, or operational restrictions, could severely impact Optum's growth trajectory and UNH's over...
Red Flags
- 🚩DOJ criminal and civil investigation: Presents an unquantified but potentially significant regulator...
- 🚩Reported membership contracting by 1.3 million in 2026 (from secondary source): If verified in futur...
- 🚩Very low insider ownership (0.28%): While common for mega-caps, it suggests less direct alignment wi...
Competitive Moat
IFRX
Rating
🛡️ Narrow
Trend
➡️ Stable but vulnerable
UNH
Rating
🛡️ Wide
Trend
➡️ Stable to Expanding
Investment Thesis
InflaRx represents an extremely high-risk, high-reward investment focused on the successful commercialization of its EU-approved orphan drug, Gohibic, for ANCA-associated vasculitis. Despite a clear market opportunity and unique drug profile, the company faces immediate existential financial challenges due to a critically short cash runway and slow sales uptake. A successful, non-dilutive financin...
Full IFRX AnalysisIf Optum continues to expand its health services and technology footprint at high-single-digit to low-double-digit rates, while UnitedHealthcare maintains stable profitability and manages its medical loss ratio, then UNH will deliver consistent EPS growth (high-single digits) and dividend increases. This makes UNH a reliable compounder for long-term capital appreciation and income, not a high-grow...
Full UNH AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
InflaRx (IFRX) remains a highly speculative, high-risk, high-reward biotech play with theoretical 10x potential if critical hurdles are overcome. The EU-approved orphan drug, Gohibic, for ANCA-associated vasculitis offers a strong market opportunity and a unique mechanism of action. However, the company's financial health is critically weak, with an estimated cash runway of 7-10 months remaining from March 2026. Commercialization of Gohibic continues to be slower than required to achieve self-su...
Full IFRX AnalysisUnitedHealth Group (UNH) remains a robust, high-quality mega-cap in the mature and highly regulated healthcare sector. Q1 2026 adjusted EPS of $7.23, a recent dividend increase to $2.32, and some analyst upgrades (e.g., Truist to $440, Goldman Sachs Conviction Buy) reflect solid operational performance and financial strength. However, these are characteristics of a stable compounder, not a company capable of 10x growth within 3-5 years. Its immense scale, market maturity, and regulatory landscap...
Full UNH AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.